Akèy › Myelom Miltip › Washington › Seattle
Etid klinik pou Myelom Miltip nan Seattle, WA
22 etid pou Myelom Miltip ap chèche patisipan nan sit nan ak bò kote Seattle (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Ap rekriteFaz 3
- Research Site, Seattle
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Ap rekriteFaz 1/2
- University of Washington, Seattle
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
Ap rekriteFaz 2
- University of Washington, Seattle
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Ap rekriteFaz 2
- Swedish Cancer Institute, Seattle
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Ap rekriteFaz 3
- Fred Hutchinson Cancer Research Center, Seattle
Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma
Ap rekriteFaz 1/2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Collection of Tissue Samples for Cancer Research
Ap rekriteEtid obsèvasyon
- Fred Hutchinson, Seattle
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Ap rekriteFaz 2
- Fred Hutchinson Cancer Center, Seattle
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Ap rekriteFaz 3
- Saint Joseph Medical Center Hematology and Oncology - Silverdale, Silverdale · 17 mi lwen
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Ap rekriteFaz 1/2
- Research Site, Seattle
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Ap rekriteFaz 3
- Research Site, Seattle
- Research Site, Seattle
Selinexor and Backbone Treatments of Multiple Myeloma Patients
Ap rekriteFaz 1/2
- Fred Hutch Cancer Center, Seattle
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
Ap rekriteFaz 1
- Fred Hutchinson Cancer Center. /ID# 267940, Seattle
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Ap rekriteFaz 1
- VA Puget Sound Health Care System, Seattle
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Ap rekriteFaz 3
- Swedish Medical Center-Ballard Campus, Seattle
- Swedish Medical Center-Cherry Hill, Seattle
- Swedish Medical Center-First Hill, Seattle
- ak 1 plis
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
Ap rekriteFaz 1
- Fred Hutchinson Cancer Center, Seattle
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
Ap rekriteFaz 1
- Swedish Medical Center - Seattle /ID# 268052, Seattle
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
Ap rekriteFaz 1/2
- Swedish Cancer Institute, Seattle
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
Ap rekriteFaz 1
- Swedish Medical Center, Seattle
PRO and Wearable Data Insights From Individuals With R/R Multiple Myeloma
Ap rekrite
- University of Washington, Seattle
Real World Insights During Treatment for Relapsed/Refractory Multiple Myeloma with Isatuximab
Ap rekrite
- University of Washington, Seattle
Evaluating the Uptake and Utility of Clinical Pathways for Newly Diagnosed Patients With Multiple Myeloma
Ap rekriteEtid obsèvasyon
- All4Cure, Seattle
Etid Myelom Miltip nan lòt vil
- New York City, NY60 etid
- Boston, MA42 etid
- Atlanta, GA41 etid
- Houston, TX38 etid
- Durham, NC37 etid
- Nashville, TN32 etid
- Denver, CO27 etid
- Columbus, OH24 etid
- Rochester, MN24 etid
- St. Louis, MO24 etid
- Baldwin Park, CA23 etid
- Chicago, IL22 etid
Lòt etid nan Seattle
- Kansè Poumon ki pa ti selil53 etid
- Kansè (tout kalite)49 etid
- Kansè pwostat44 etid
- Leksemi mieloïd egi40 etid
- Kansè nan tete40 etid
- Kansè Metastatik39 etid
- Kansè kolorektal34 etid
- Kansè poumon33 etid
- Kansè ovè31 etid
- Kansè pankreyas22 etid
- Kansè vejik21 etid
- Lukemi lenfositè kwonik21 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 2, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.